疑似早产子痫前期孕妇重复胎盘生长因子检测(PARROT-2):多中心、平行组、优效性随机对照试验
PARROT-2为在英格兰、苏格兰和威尔士22个产科单位开展的多中心、平行组、优效性随机对照试验,纳入22周0天至35周6天、疑似子痫前期的18岁及以上孕妇1253例,1:1随机分为揭示重复PlGF检测组(625例)与常规护理下 conceal 重复检测组(627例)。主要终点为围产期复合结局(死产、早期新生儿死亡或新生儿病房入院),揭示组31.2%(195/625)vs conceal组27.8%(174/626),相对风险1.21(95%CI 0.95-1.33),p=0.18,无显著差异;符合方案分析结果相似。作者结论:重复PlGF检测未改善围产期结局,在高收入、不良结局低发生率背景下不推荐对所有疑似子痫前期个体常规重复检测。
要点
- 疑似早产子痫前期(22周0天至35周6天)孕妇重复PlGF检测未改善围产期复合结局:揭示组31.2%(195/625)vs conceal组27.8%(174/626),RR 1.21(95%CI 0.95-1.33),p=0.18。
- 主要终点为死产、早期新生儿死亡或新生儿病房入院的围产期复合结局,符合方案分析结果与意向性分析相似。
- 揭示组严重不良事件4例、conceal组6例,站点主要研究者和主要研究者均判定与干预无关。
- 作者结论:在高收入、不良结局低发生率背景下,不推荐对所有疑似子痫前期个体常规重复PlGF检测。
适用人群与场景
- 年龄18岁及以上、孕22周0天至35周6天、疑似子痫前期的孕妇,来自英格兰、苏格兰和威尔士22个产科单位。
处置流程与药物剂量
- 揭示组采用基于PlGF的临床管理算法及国家推荐阈值进行重复检测;conceal组重复检测结果对临床团队隐藏并按常规护理管理。
- 干预未对孕妇、伴侣、临床医生或数据收集者设盲;试验统计师对干预分配设盲。
研究设计与关键结果
- 多中心、平行组、优效性随机对照试验,22个产科单位,纳入1253例疑似早产子痫前期孕妇,1:1随机;1例因随机化错误排除;揭示组625例,conceal组627例(平均年龄32.3岁[SD 5.7];879例[70%]为白人);conceal组1例失访。
- 主要围产期复合结局(死产、早期新生儿死亡或新生儿病房入院):揭示组31.2%(195/625)vs conceal组27.8%(174/626),相对风险1.21(95%CI 0.95-1.33),p=0.18,无显著差异;符合方案分析结果相似。
- 严重不良事件:揭示组4例 vs conceal组6例,站点主要研究者和主要研究者均判定与干预无关。
证据类型、等级与局限
- 证据类型:多中心、平行组、优效性随机对照试验(RCT)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论:在高收入、不良结局低发生率背景下,不推荐对所有疑似子痫前期个体常规重复PlGF检测。
- 重复PlGF检测未改善围产期结局,不能据此改变对疑似早产子痫前期孕妇的常规管理。
指南或共识出处
- PARROT-2试验,ISRCTN 85912420,发表于Lancet。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Placental growth factor (PlGF)-based testing has high diagnostic accuracy for predicting pre-eclampsia needing delivery, significantly reducing time to diagnosis and severe maternal adverse outcomes. The clinical benefit of repeat PlGF-based testing is unclear. We aimed to determine whether repeat PlGF-based testing (using a clinical management algorithm and nationally recommended thresholds) reduces adverse perinatal outcomes in pregnant individuals with suspected preterm pre-eclampsia.
METHODS: In this multicentre, parallel-group, superiority, randomised controlled trial, done in 22 maternity units across England, Scotland, and Wales, we recruited women aged 18 years or older with suspected pre-eclampsia between 22 weeks and 0 days of gestation and 35 weeks and 6 days of gestation. Women were randomly assigned (1:1) to revealed repeat PlGF-based testing or concealed repeat testing with usual care. The intervention was not masked to women or partners, or clinicians or data collectors, due to the nature of the trial. The trial statistician was masked to intervention allocation. The primary outcome was a perinatal composite of stillbirth, early neonatal death, or neonatal unit admission. The primary analysis was by the intention-to-treat principle, with a per-protocol analysis restricted to women managed according to their allocation group. The trial was prospectively registered with the ISRCTN registry, ISRCTN 85912420.
FINDINGS: Between Dec 17, 2019, and Sept 30, 2022, 1253 pregnant women were recruited and randomly assigned treatment; one patient was excluded due to randomisation error. 625 women were allocated to revealed repeat PlGF-based testing and 627 women were allocated to usual care with concealed repeat PlGF-based testing (mean age 32·3 [SD 5·7] years; 879 [70%] white). One woman in the concealed repeat PlGF-based testing group was lost to follow-up. There was no significant difference in the primary perinatal composite outcome between the revealed repeat PlGF-based testing group (195 [31·2%]) of 625 women) compared with the concealed repeat PlGF-based testing group (174 [27·8%] of 626 women; relative risk 1·21 [95% CI 0·95-1·33]; p=0·18). The results from the per-protocol analysis were similar. There were four serious adverse events in the revealed repeat PlGF-based testing group and six in the concealed repeat PlGF-based testing group; all serious adverse events were deemed unrelated to the intervention by the site principal investigators and chief investigator.
INTERPRETATION: Repeat PlGF-based testing in pregnant women with suspected pre-eclampsia was not associated with improved perinatal outcomes. In a high-income setting with a low prevalence of adverse outcomes, universal, routine repeat PlGF-based testing of all individuals with suspected pre-eclampsia is not recommended.
FUNDING: Tommy's Charity, Jon Moulton Charitable Trust, and National Institute for Health and Care Research Guy's and St Thomas' Biomedical Research Centre.
参考来源
- Hurrell A, Webster L, Sparkes J, et al. Repeat placental growth factor-based testing in women with suspected preterm pre-eclampsia (PARROT-2): a multicentre, parallel-group, superiority, randomised controlled trial. Lancet. 2024. PMID: 38342128. doi:10.1016/S0140-6736(23)02357-7
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。